Table 1.
Reported adverse events | Incidence |
---|---|
Non-severe | |
Skin irritation4,5,20,21,23,25–31,36,37 | Common |
Allergic skin reaction5,6 | Very rare |
Discomfort and pain7 | Common |
Forefoot oedema and lymphoedemaa | Rare |
Bacterial and fungal infection4,9,10 | Very rare |
Severe | |
Soft tissue damage or necrosis20–30,34–37,62 | Very rare |
Nerve damage31–37 | Very rare |
Arterial impairment24,77 | Very rare |
Venous thromboembolism43 | Very rare |
Cardiac decompensation47 | Very rare |
Frequency grouping: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to < 1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), frequency not known (cannot be estimated from the available data).89
aBased on experts’ experience.
Source: reproduced with permission from European Commission, 2009.89